WEQUAL-GLOBAL
17.11.2020 15:44:08 CET | Business Wire | Press release
Twenty-four female executives of leading EMEA companies have been identified as having the leadership traits for top level C-suite positions. The WeQual Awards (www.wequal.com/awards ) identify already successful senior women who are one level below C-suite, and are aimed at tackling the slow progress in appointing women to executive roles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005907/en/
A quarter of the winners of previous UK and US WeQual Awards have since been promoted to the executive committees of FTSE and Fortune 500 companies.
“The glass-ceiling concept has been an issue for decades, and the drop-off is steepest just below the C-suite, so I launched WeQual to champion gender equality at the top,” says Katie Litchfield , founder and CEO of WeQual.
The EMEA finalists are from a wide range of sectors and companies, including Orange, Unilever, Schneider Electric, Bayer Consumer Health, ENGIE, KCB Group, Sodexo, Enel Group, L'Oréal, Mondi Group, Bureau Veritas, Standard Chartered, Veolia Environnement, Ericsson, Fresenius Medical Care, AkzoNobel, Ooredoo Qatar, Danone, Aryzta.
The 24 finalists were assessed against seven criteria: Leadership, Cognitive Ability, Integrity, Drive & Resilience, Equality, Knowledge of the Business, and Personal Development. All candidates were assessed blind with no name or company revealed in their application.
Eight executive interviewers will hold 30-minute interviews with the three finalists in their category before each choosing a category winner: Brand Innovation, Commercial Performance, Digital Impact, Finance, Head of Region, People Excellence, Strategy Development, and Transformational Leadership.
The finalists will be announced in December 2020.
Among supporters of the awards are Ann Cairns, Executive Chair of Mastercard and Global Chair of the gender equality campaign group ‘30% Club’; Sir Ian Cheshire, Chairman of Barclays; Dame Inga Beale; and Ron Kalifa OBE of Network International. They are part of a roster of well-known C-suite executives who will now choose eight category winners.
Sir Ian Cheshire says: "These awards are among the first to target women at this level. We believe building awareness of these talented people, as well as connecting them to each other, is an important step in improving diversity at top levels of business.”
This senior group of 24 executives will become members of the WeQual Club and join the existing 72 senior FTSE and Fortune 500 female executives.
(Ends)
Notes to editors
Methodology: The eight assessment questions were developed from a research-based meta-analysis of the factors and characteristics that mark leaders as different from non-leaders (Kirkpatrick and Locke, 1991). They were designed to help the women best describe how they deliver on leadership characteristics and how they are seen by others as a leader, and indeed engage people who see them as fit to lead.
About WeQual
WeQual's mission is to make businesses more inclusive by identifying exceptional women executives and address the gender imbalance across the world's Executive Committees. Katie Litchfield, founder and CEO of WeQual Awards, devised the new platform which calls for women senior executives to build their case as to why they are deserving to be appointed to the Executive Committee.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005907/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
